Abstract P6-13-11: Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer

CONCLUSION: The combination of alpelisib and T-DM1 appears to be safe, well tolerated, with clinical activity in HER2-positive MBC patients including those who progressed on prior T-DM1 therapy. The study is currently in dose expansion with goal of enrolling 10 additional patients with T-DM1 and alpelisib 250 mg daily.Citation Format: Jain S, Nye L, Santa-Maria C, Bontemps L, Williams A, Garrett H, Dammrich E, Giles F, Gradishar W. Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-11.

Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Jain, S., Nye, L., Santa-Maria, C., Bontemps, L., Williams, A., Garrett, H., Dammrich, E., Giles, F., Gradishar, W. Tags: Poster Session Abstracts Source Type: research